Thiozanthene derivatives as delta-opioid modulators

Details Thiozanthene derivatives as delta-opioid modulators Thiozanthene derivatives as delta-opioid modulators

2011-07-19

2011-07-19

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S304000

Reexamination Certificate

active

07982042

ABSTRACT:
The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

REFERENCES:
patent: 2368006 (1945-01-01), Cusic
patent: 2784185 (1957-03-01), Schuler
patent: 2901478 (1959-08-01), Schuler
patent: 3179665 (1965-04-01), Schmutz
patent: 3305547 (1967-02-01), Stach et al.
patent: 3470188 (1969-09-01), Kaiser et al.
patent: 3557287 (1971-01-01), Berde et al.
patent: 3931232 (1976-01-01), Bender et al.
patent: 3987042 (1976-10-01), Gueremy et al.
patent: 4086350 (1978-04-01), Zirkle
patent: 4275209 (1981-06-01), Lassen et al.
patent: 4356184 (1982-10-01), Deason et al.
patent: 4666907 (1987-05-01), Fortin et al.
patent: 4777177 (1988-10-01), Traber et al.
patent: 5502049 (1996-03-01), Garret et al.
patent: 6004983 (1999-12-01), Andersen et al.
patent: 6114354 (2000-09-01), Andersen et al.
patent: 6153626 (2000-11-01), Pelcman et al.
patent: 7060711 (2006-06-01), Lubbert et al.
patent: 7432257 (2008-10-01), Coats et al.
patent: 7439239 (2008-10-01), Coats et al.
patent: 7553850 (2009-06-01), Dax et al.
patent: 2003/0018447 (2003-01-01), Florschuetz
patent: 2003/0166672 (2003-09-01), Lubbert et al.
patent: 2005/0009860 (2005-01-01), Carson et al.
patent: 2006/0030585 (2006-02-01), Dax et al.
patent: 2006/0135522 (2006-06-01), Carson et al.
patent: 2006/0135524 (2006-06-01), Carson et al.
patent: 2006/0135763 (2006-06-01), Coats et al.
patent: 2006/0148823 (2006-07-01), Coats et al.
patent: 2006/0287297 (2006-12-01), DeCorte et al.
patent: 2008/0318937 (2008-12-01), Coats et al.
patent: 2009/0042871 (2009-02-01), Coats et al.
patent: 2009555 (1970-10-01), None
patent: 0005607 (1979-11-01), None
patent: 1049676 (2000-11-01), None
patent: 1306376 (2003-05-01), None
patent: 1321169 (2003-06-01), None
patent: 2290202 (1976-06-01), None
patent: 1128734 (1966-07-01), None
patent: WO 9828275 (1998-07-01), None
patent: WO 9900376 (1999-01-01), None
patent: WO 0146191 (2001-06-01), None
patent: WO 0166543 (2001-09-01), None
patent: WO 0172303 (2001-10-01), None
patent: WO 0236573 (2002-05-01), None
patent: WO 0248122 (2002-06-01), None
patent: WO 03035646 (2003-05-01), None
patent: WO 2004026030 (2004-04-01), None
patent: WO 2004035541 (2004-04-01), None
patent: WO 2004092165 (2004-10-01), None
patent: WO 2005003131 (2005-01-01), None
Sindelar, K., et al: Aminoalkylidene and Aminoalkyl Derivatives of 6,11-Dihydrodibenzo[be,e]Thiepin-2-and-9-Carbonitrile and 4,10-Dihydrothieno[2,3-e]-1-Benzothiepin-6-Carbonitrile; Antipressants with a New Activity Profile, Collection of Czechoslovak Chemical Communications (1988), vol. 63, No. 2, pp. 340-360.
Ananthan, S.: The AAPS Journal 2006, 8(1): E118-E125.
Berge, S.M. et al.: Pharmaceutical Salts; J. of Pharmaceutical Sciences (1977) 66(1): 1-19.
Bidlack, J.M. et al.: 8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan; The J. of Pharm. & Exper. Therapeutics (2002) 302(1): 374-380.
Biemans et al.: Journal of Organic Chemistry, 1996, 61:9012-9015.
Boyd, R.E. et al.: Synthesis and Binding Affinities of 4-Diarylaminotropanes, a New Class of Delta Opioid Agonists; Bioorg. & Med. Chem. Letters (2000) 10: 1109-1111.
Calderon, S.N. et al: “SNC 80 and Related Opioid Agonists”, Current Pharmaceutical Design, 2004 10:733-742.
Calo, et al.: British Journal of Pharmacology 2002, 136:303-311.
Carson, J.R. et al.,N-Alky1-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]-benzamides, μ and δ opioid agonists: a μ address; Bioorganic & Med. Chem. Letters (2004) 14:2113-2116.
Chang et al.: Molecular Pharmacology, 1984, 26:484-488.
Commercial 2-Bromo-Phenols from Sigma-Aldrich, 2007.
Commercial 4-piperidinones, 2007.
Connor, M. et al.: Opioid Receptor Signalling Mechanisms; Clinical and Exper. Pharmacology and Physiology (1999) 26: 493-499.
Dorwald, F.Z.: Side Reactions in Organic Synthesis (2005) Wiley: VCH, Weinheim p. 1X of Preface: 1-15.
Dörwald, F.Z.: Side Reactions in Organic Synthesis (2005) Wiley: VCH, Weinheim p. 1X of Preface & Chapter 8: 279-308.
Erchegyi et al.: Journal of Medicinal Chemistry, 2003, 46:5587-5596.
Frontier Scientific Catalog (Logan, UT) Advanced Discovery Chemicals Pure (and not so) Simple 2006; Discover Chemicals A-F, H-I, M-N, P-Q and T.
Frontier Scientific Catalog (Logan, UT) online http://www.frontiersci.com/browse.php?browse=Boronic%20acid Apr. 28, 2007.
Furness, M.S. et al.: Probes and Narcotic Receptor-Mediated Phenomena. 27.1Synthesis and Pharmacological Evaluation of Selective δ-Opioid Receptor Agonists from 4-[αR)-α-(2S,5R)-4- Substituted-2,5-demethyl-1-piperazinyl-3-methoxybenzyl-]-N,N-diethylbenzamides and Their Enantiomers; J. Med. Chem. (2000) 43:3193-3196.
Gilbert, P.E. et al.: The Effects of Morphine- and Nalorphine-Like Drugs in the Nondependent, Morphine-Dependent and Cyclazocine-Dependent Chronic Spinal Dog; The J. of Pharm. and Exp. Thera. (1976) 198(1): 66-82.
Gould, P.L.: Salt selection for basic drugs; Intl J. of Pharmaceutics (1986) 33: 201-217.
Gribble, G.W. et al.: Sodium Triacetoxyborohydride1; Encyclopedia of Reagents for Organic Synthesis online @ http://www.mrw.interscience.wiley.com/eros/articles/rs112/sect0.html Apr. 24, 2007.
Gross, R.A. et al.: Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents; Proc. Natl. Acad. Sci. (1990) 87: 7025-7029.
Hancock, B.C. et al.: Characteristics and Significance of the Amorphous State in Pharmaceutical Systems; J. of Pharm. Sciences (1997) 86(1): 1-12.
Hutchins, R.O. et al.: Selective Reductive Displacement of Alkyl Halides and Sulfonate Esters with Cyanoborohydride Reagents in Hexamethylphosphoramide; J. Org. Chem. (1977) 42(1): 82-91.
Jones, M. Jr.: Organic Chemistry Norton, New York (1997):578-591.
Kenakin, T. et al.: The ligand paradox between affinity and efficacy: can you be there and not make a difference?; TRENDS in Pharm. Sciences (2002) 23(6): 275-280.
Kaiser, C. et al,: “Analogs of Phenothiazines. 5. Synthsis and Neuropharmacological Activity of Some Piperidylidene Derivatives of Thioxanthenes, Xanthenes, Dibenzoxepins, and Acridans.” J. Med. Chem., 1974:57-61, vol. 17, No. 1.
Kruzsynski et al.: Journal of Peptide Research, 2005, 66:125-131.
Le Bars, D. et al.: Animal Models of Nociception; Pharmacological Reviews (2001) 53: 597-652.
Lord, John A.H. et al.: Endogenous opioid peptides: multiple agonists and receptors; Nature (1977) 267: 495-499.
Loughhead, David G.: Tetrahedron Letters, 1998, 5701-5702.
Mansour, A. et al.: Anatomy of CNS opioid receptors; TRENDS in Neuroscience (1988) 11(7): 308-314.
Nies and Speilberg, Goodman & Gilman, The Pharmacological Basis of Therapeutics, 1996, pp. 47, 58, Ninth Edition, vol. 1, McGraw-Hill, Interamericana, Mexico.
Nieschulz, O. et al.: “Pharmacological studies on 10-(1-methyl-3-piperidyl)-2 methoxyphenothiazine and related compounds”; Arzneimittel-Forschung 1960, 10, 156-165.
Pert, C.B. et al.: Opiate Receptor: Demonstration in Nervous Tissue; Science (1973) 179: 1011-1014.
Pozharskii et al.: Heterocycles in Life and Society, Wiley, 1997, pp. 1-6.
Quock, R.M. et al.: The δ-Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy; Pharmacological Reviews (1999) 51(3): 503-532.
Sharma, S.K. et al.: Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance; Proc. Natl. Acad. Sci. (1975) 72(8): 3092-3096.
Still, W. Clark et al.: Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution; J. Org. Chem. (1978) 43(14): 2923-2925.
Structures in copending U.S. Appl. No. 11/195,231.
Sun, X. et al.: Synthesis and Opioid Receptor Binding Properties of Conformation-Rigidified Analogues of 8-Carboxamidocyclazocine and 8-Formamidocyclazocine; Abstract of Papers 229thACS Natl Meeting NY 2005.
Tao, et al.: Bioorganic & Medicinal Chemistry Letters,

Affiliated with

Also associated with

Rating

Thiozanthene derivatives as delta-opioid modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiozanthene derivatives as delta-opioid modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiozanthene derivatives as delta-opioid modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2697555